Acupuncture for Anxiety and Depression
The study aims to primarily investigate the effects and safety of acupuncture on anxiety and depression among patients with breast cancer.
Anxiety and Depression|Breast Cancer Survivor
DEVICE: Electroacupuncture|DEVICE: Sham electroacupuncture
The change from baseline in the Hospital Anxiety and Depression Scale (HADS), The HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression., week 8
The change from baseline in the HADS, The HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression., weeks 4, 12, 16 and 20|The change from baseline in the HADS-A and HADS-D, The HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression., weeks 4, 8, 12, 16 and 20|Proportion of participants with a total HADS score less than 15, an HADS-A score of less than or equal to 7, and an HADS-D score of less than or equal to 7, The HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression., weeks 4, 8, 12, 16 and 20|The change from baseline in the Generalized Anxiety Disorder 7-item scale (GAD-7), The GAD-7 self-assessment scale can be used for the preliminary evaluation of generalized anxiety symptoms. A score of 0 - 4 indicates no anxiety symptoms, a score of 5 - 9 indicates mild anxiety, a score of 10 - 14 indicates moderate anxiety, and a score of 15 or higher indicates severe anxiety., weeks 4, 8, 12, 16 and 20|The change from baseline in the Patient Health Questionnaire - 9 (PHQ-9), The PHQ-9 scale is commonly used for screening depressive symptoms. This scale consists of nine items, evaluating depressive symptoms by asking how much of the time the individual has been bothered by each of the nine aspects over the past two weeks. The scoring interpretation is as follows: 0 - 4 points indicate no depressive symptoms, 5 - 9 points indicate mild depressive symptoms, 10 - 14 points indicate moderate depressive symptoms, 15 - 19 points indicate relatively severe depressive symptoms, and 20 - 27 points indicate severe depressive symptoms. It is generally considered that a PHQ-9 score of 10 or higher, or sometimes 8 or higher, is clinically significant., weeks 4, 8, 12, 16 and 20|Change from baseline in Hamilton Depression Scale-14, The Hamilton Depression Scale (HAMD) was developed by Hamilton in 1959 and is a clinical tool used to assess anxiety symptoms. All items use a 5-point rating scale from 0 to 4, with a total score ranging from 0 to 56. The cut-off value is 14 points. Generally, a score of \>14 points indicates anxiety, \>29 points indicates severe anxiety, and the higher the score, the more severe the anxiety symptoms., Week 4, 8, 12, 16, 20|Change from baseline in Hamilton Depression Scale-17, The Hamilton Depression Scale (HAMD) was developed by Hamilton in 1960 and is the most commonly used scale in clinical assessment of depressive states. All items are scored on a 5-point scale ranging from 0 to 4. The total score is 68. A score of 8-17 indicates mild depression, 18-24 indicates moderate depression, and a score of â‰¥25 indicates severe depression., Week 4, 8, 12, 16, 20|The change from baseline in the Functional Assessment of Cancer Therapy- General and the Functional Assessment of Cancer Therapy-Breast Cancer(FACT-B), The FACT-B is a specific scale designed to measure the quality of life in breast cancer patients, with higher scores indicating worse quality of life., weeks 4,8, 12 and 20|The change from baseline in the Fear of Cancer Recurrence Inventory-short form(FCRI-SF), The FCRI-SF score ranges from 0 to 168, with higher scores indicating a higher level of fear of cancer recurrence among cancer patients., weeks 4, 8, 12 and 20|The change from baseline in the brief fatigue inventory (BFI), The BFI score ranges from 0 to 10, with higher scores indicating greater fatigue., weeks 4, 8, 12, and 20|The change from baseline in the Insomnia Severity Index (ISI), The ISI score ranges from 0 to 28, with higher scores indicating Insomnia Severity., weeks 4, 8, 12 and 20|The proportion of responders per the Patient Global Index of Improvement (PGI-I), The PGI-I evaluates the overall treatment effect perceived by patients themselves. The change can be rated in 7 levels, including "very much better", "much better", "a little better", "no change", "a little worse", "much worse" or "very much worse"., weeks 8 and 20
Expectance assessment, Participants will be asked: How do you expect your anxiety and depression will be in 8 weeks?, baseline|Assessment of belief in acupuncture, Participants will be asked the question: Do you think your anxiety and depression may be helped by acupuncture?, baseline and week 8|Blinding assessment, Participants will be asked the question: Do you think you have received traditional electroacupuncture in the past 8 weeks?, week 8|Adherence assessment, Adherence will be assessed via counting treatment sessions. Those who complete over 80% treatment sessions will be defined as of good adherence., through study completion, an average of five months|Proportion of participants using rescue medicine., The percentage of patients using other medications or therapies that may affect their anxiety and depression., through study completion, an average of five months|Safety assessment, Adverse events and severe adverse events will be recorded in the case report form, whether related to interventions or not., through study completion, an average of five months
The study aims to primarily investigate the effects and safety of acupuncture on anxiety and depression among patients with breast cancer.